Sign In
Buy CVAC
$4.66
+0 (+0%)
At Close: Apr 02, 2026
CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE
04:30pm, Thursday, 27'th Mar 2025
European Patent Office largely dismisses opposition filed by BioNTech SE in April 2023 challenging validity of EP 3 708 668 B1 and maintains the patent in amended form A hearing on infringement of EP
CureVac Earns Repeat Recognition by LexisNexis(R) as One of the World's Top Innovators
07:15am, Tuesday, 18'th Feb 2025
CureVac among global top 100 most fast-paced innovators for third consecutive year in acknowledgment of its innovative strength and extensive intellectual property portfolio The company holds one of t
CureVac: Latest GBM Data Bodes Well For Next Program Check Point
04:55pm, Wednesday, 08'th Jan 2025
CureVac N.V.'s CVGBM vaccine showed positive safety and immunogenicity data in Part A of its phase 1 study for resected glioblastoma, with no dose-limiting toxicities. Key catalysts include Part B CVG
2 Small-Cap Stocks Set to Shine in a Bull Market
07:30am, Monday, 16'th Dec 2024
Small-cap stocks often experience outsized gains during bullish markets. Their smaller market capitalizations and growth-oriented profiles make them more sensitive to improving economic conditions, wh
Is the Options Market Predicting a Spike in CureVac (CVAC) Stock?
12:21pm, Wednesday, 20'th Nov 2024
Investors need to pay close attention to CureVac (CVAC) stock based on the movements in the options market lately.
CureVac N.V. (CVAC) Q3 2024 Earnings Call Transcript
03:08pm, Tuesday, 12'th Nov 2024
CureVac N.V. (NASDAQ:CVAC ) Q3 2024 Earnings Conference Call November 12, 2024 9:00 AM ET Company Participants Sarah Fakih - Vice President of Corporate Communications and Investor Relations Alexander
CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2024 and Provides Business Update
07:20am, Tuesday, 12'th Nov 2024
Strengthened Cash, Strategic Refocus and Pipeline Progress Define Transformative Quarter €400 million upfront payment from restructured GSK collaboration reflected in financials, cash position incre
CureVac to Report Third Quarter and First Nine Months 2024 Financial Results and Business Update on November 12, 2024
07:30am, Thursday, 07'th Nov 2024
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 7, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based
Experienced CFO and investment banker with 30-year track record will help drive CureVac's transformation TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 4, 2024 / CureVac N.V. (Nasdaq:CVAC)
CureVac to Present at the 12th International mRNA Health Conference
07:15am, Monday, 04'th Nov 2024
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 4, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based
CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
08:10am, Monday, 28'th Oct 2024
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / October 28, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based
Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents
05:50am, Tuesday, 08'th Oct 2024
Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's High Court.
Preliminary immunogenicity results demonstrate induction of cancer antigen-specific T-cell responses in 77% of evaluable patients following CVGBM monotherapy 84% of immune responses were de novo, obse
CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
07:15am, Thursday, 12'th Sep 2024
Phase 2 data demonstrated positive immune responses to A and B strains, with acceptable safety and reactogenicity profile, meeting all pre-defined study endpoints Vaccine candidate based on CureVac's
CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress
07:15am, Monday, 09'th Sep 2024
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / September 9, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based
